Phase 3
Idiopathic Pulmonary Fibrosis
Intervention Type
Inhaled Drug
Funder Type

Drug Details

Inhaled treprostinil is an inhaled medication approved for the treatment of pulmonary arterial hypertension in World Health Organization (WHO) Group 1 patients. Inhaled treprostinil is a synthetic analogue of prostacyclin, a naturally occurring substance in the body, which has effects on dilating blood vessels. Inhaled treprostinil was approved for PAH by the United States Food and Drug Administration (FDA) in 2009. 

Study Purpose

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Patients with Chronic Fibrosing Interstitial Lung Disease.

This drug has no clinical trials actively recruiting patients at this time.


footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >